Note: In Table 19 each row gives XARELTO (N=7081) n (%) and event rate per 100 patient-years, then warfarin (N=7090) n (%) and event rate, then the hazard ratio (95% CI) where one is given. ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.
Does Xarelto cause more bleeding than warfarin (ROCKET AF)?
Note: In Table 5 each row gives XARELTO (N=7111) n (%/year), warfarin (N=7125) n (%/year), and the hazard ratio (95% CI). The atrial fibrillation page of the Xarelto HCP site, as captured on November 13, 2026, shows the non-intracranial fatal bleeding confidence interval as 0.07-0.32; the Prescribing Information gives (0.07, 0.82). ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.
Has Xarelto been studied for cardioversion in atrial fibrillation?
Note: The first passage is from the Prescribing Information; the others are from the atrial fibrillation page of the Xarelto HCP site. ROCKET AF compared XARELTO 20 mg once daily (15 mg once daily for CrCl 30 to 50 mL/min) with warfarin titrated to INR 2.0 to 3.0 in patients with nonvalvular atrial fibrillation at increased risk of stroke, followed on study treatment for a median of 590 days.
Subgroup results
Xarelto 15 mg in moderate kidney impairment: what were the ROCKET AF results?
This passage is in a collapsed section of the page; select: What were the clinical results for patients with moderate renal impairment receiving a 15-mg dose of XARELTO®?
This passage is in a collapsed section of the page; select: What were the clinical results for patients with moderate renal impairment receiving a 15-mg dose of XARELTO®?
Note: This is a subgroup analysis of ROCKET AF (Fox et al., Eur Heart J 2011, cited on the FAQ page); the comparator in each renal subgroup was warfarin.